These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 31961981)

  • 1. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
    Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
    Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
    Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
    Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
    Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
    Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
    Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
    JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
    Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
    Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
    Kranzler HR; Armeli S; Covault J; Tennen H
    Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients.
    Foulds JA; Ton K; Kennedy MA; Adamson SJ; Mulder RT; Sellman JD
    Pharmacogenet Genomics; 2015 May; 25(5):270-3. PubMed ID: 25715171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.
    Morley KC; Kranzler HR; Luquin N; Jamshidi N; Adams C; Montebello M; Tremonti C; Dali G; Logge W; Baillie A; Teesson M; Trent R; Haber PS
    Am J Psychiatry; 2024 May; 181(5):403-411. PubMed ID: 38706338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
    Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
    Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
    Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP
    Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
    Ray LA; Bujarski S; Chin PF; Miotto K
    Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.
    Arias AJ; Gelernter J; Gueorguieva R; Ralevski E; Petrakis IL
    Am J Addict; 2014; 23(3):288-93. PubMed ID: 24724887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.
    Oroszi G; Anton RF; O'Malley S; Swift R; Pettinati H; Couper D; Yuan Q; Goldman D
    Alcohol Clin Exp Res; 2009 Mar; 33(3):383-93. PubMed ID: 19053977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
    Ray LA; Hutchison KE
    Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation.
    Ray LA; Hutchison KE; Ashenhurst JR; Morrow AL
    Alcohol Clin Exp Res; 2010 Aug; 34(8):1479-87. PubMed ID: 20528823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
    Lin Y; Kranzler HR; Farrer LA; Xu H; Henderson DC; Zhang H
    Pharmacogenomics J; 2020 Oct; 20(5):672-680. PubMed ID: 32029903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial.
    O'Malley SS; Robin RW; Levenson AL; GreyWolf I; Chance LE; Hodgkinson CA; Romano D; Robinson J; Meandzija B; Stillner V; Wu R; Goldman D
    Alcohol Clin Exp Res; 2008 Jul; 32(7):1271-83. PubMed ID: 18482155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.
    Oslin DW; Berrettini W; Kranzler HR; Pettinati H; Gelernter J; Volpicelli JR; O'Brien CP
    Neuropsychopharmacology; 2003 Aug; 28(8):1546-52. PubMed ID: 12813472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
    Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
    Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
    Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.